Detecting Liver Fibrosis in Chronic Liver Disease Using New Biomarkers Beyond Standard Tests

What this Trial Is About

Researchers are studying chronic liver disease CLD, a condition where liver fibrosis, or scarring, disrupts normal liver function. This research focuses on the role of hepatic stellate cells HSCs that become activated when liver cells are damaged, leading to fibrosis. Current biomarkers do not effectively measure HSC activation, which may be a more sensitive indicator than fibrosis itself. The study aims to find biomarkers that better reflect the stage of liver fibrosis in a large group of patients with CLD from various causes. Participants will have blood samples taken using EDTA tubes to analyze biomarkers linked to liver fibrosis. The study is interventional and involves collecting blood to correlate biomarker levels with fibrosis stages. This procedure occurs at the beginning of the study, with no mention of additional treatments or study arms. During the study, participants will undergo blood draws and a transient elastography test Fibroscan4 to assess liver fibrosis. Researchers will monitor the correlation between biomarker levels in blood and the liver fibrosis stage. The main measurement occurs on the first day, and safety and eligibility are closely checked. The study will continue until January 2028, involving adults aged 18 and older with chronic liver disease.

Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers